Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.
Imaging
MTC
Medullary Thyroid Carcinoma
PET/CT
Ultrasonography
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
05
08
2021
accepted:
26
10
2021
pubmed:
9
11
2021
medline:
24
3
2022
entrez:
8
11
2021
Statut:
ppublish
Résumé
Medullary thyroid carcinoma (MTC) originates from thyroid parafollicular C-cells and represents <5% of all thyroid cancers. Serum Calcitonin (CTn) is considered the most sensitive marker of persistent or recurrent disease and is measured in association to CEA. According to the American Thyroid Association (ATA) guidelines, following initial surgery when CTn level remains below 150 pg/mL, follow-up may rely on repeated serum marker determinations and on neck ultrasonography (US). When CTn level exceeds 150 pg/ml, additional imaging is required. In this review, we provide an overview of available imaging tools to monitor MTC course and propose an effective imaging strategy for MTC patients according to their clinical situation. A literature search focusing on available imaging tools to monitor MTC provided the currently available information for this review. Recent evidence-based reports and reviews were considered as priority over older evidence. For MTC patients with detectable CTn levels and disease recurrence, PET/CT imaging with The role of imaging in MTC patients improved, especially with the use of
Identifiants
pubmed: 34748168
doi: 10.1007/s12020-021-02930-8
pii: 10.1007/s12020-021-02930-8
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
330-337Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : 2017YTWKWH
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
S.A. Wells Jr, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel et al. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015)
pubmed: 25810047
pmcid: 4490627
J. Barbet, L. Campion, F. Kraeber-Bodere, J.F. Chatal; Group GTES, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 6077–6084 (2005)
pubmed: 16091497
A.L. Giraudet, A. Al Ghulzan, A. Aupérin, S. Leboulleux, A. Chehboun, F. Troalen et al. Progression of medullary thyroid carcinoma: assessment with Calcitonin and CEA doubling times. Eur. J. Endocrinol. 158, 239–46 (2008)
E. Fialkowski, M. De Benedetti, J. Moley, Long-term outcome of reoperations for medullary thyroid carcinoma. World J. Surg. 32, 754–65 (2008)
pubmed: 18188643
G. Pellegriti, S. Leboulleux, E. Baudin, N. Bellon, C. Scollo, J.P. Travagli et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br. J. Cancer 88, 1537–42 (2003)
pubmed: 12771918
pmcid: 2377113
J.A. van Heerden, C.S. Grant, H. Gharib, I.D. Hay, D.M. Ilstrup, Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann. Surg. 212, 395–400 (1990)
pubmed: 2222011
pmcid: 1358266
S. Asa, K. Sonmezoglu, L. Uslu-Besli, O.E. Sahin, E. Karayel, H. Pehlivanoglu et al. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Ann. Nucl. Med. 35, 900–915 (2021)
pubmed: 33993425
L. Giovanella, G. Treglia, I. Iakovou, J. Mihailovic, F.A. Verburg, M. Luster., EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 47, 61–77 (2020)
pubmed: 31482429
F. Castinetti, D. Taïeb, Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal? Thyroid 31, 151–155 (2021)
pubmed: 33191866
G. Treglia, C. Aktolun, A. Chiti, S. Frangos, L. Giovanella, M. Hoffmann et al. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine. Eur. J. Nucl. Med. Mol. Imaging 43, 1486–1490 (2016)
pubmed: 27118126
J. Leclere, S. Sidibé, N. Lassau et al. Ultrasonographic aspects of hepatic metastases of thyroid medullary cancers. Eur. J. Radiol. 77, 99–103 (1996)
S.V. Kushchayev, Y.S. Kushchayeva, S.H. Tella, T. Glushko, K. Pacak, O.M. Teytelboym, Medullary Thyroid Carcinoma: An Update on Imaging. J. Thyroid Res. 2019, 1893047 (2019)
pubmed: 31360432
pmcid: 6642782
C. Dromain, T. de Baère, E. Baudin, J. Galline, M. Ducreux, V. Boige et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. Am. J. Roentgenol. 180, 121–8 (2003)
M. Terroir, C. Caramella, I. Borget, S. Bidault, C. Dromain, K. El Farsaoui et al. F-18-dopa positron emission tomography/computed tomography is more sensitive than whole-body magnetic resonance imaging for the localization of persistent/recurrent disease of medullary thyroid cancer patients. Thyroid 29, 1457–64 (2019)
pubmed: 31530235
G. Treglia, L. Giovanella, 18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines! Eur. J. Nucl. Med. Mol. Imaging 47, 527–8 (2020)
pubmed: 31754794
C.E. Ueda, P.S. Duarte, L.A. de Castroneves, G.B. Coura-Filho, H.N. Sado, M.T. Sapienza et al. Comparison of (18)F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases. Nucl. Med. Mol. Imaging 54, 281–91 (2020)
pubmed: 33281999
pmcid: 7704988
E. Baudin, J. Lumbroso, M. Schlumberger, J. Leclere, F. Giammarile, P. Gardet et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J. Nucl. Med. 37, 912–6 (1996)
pubmed: 8683310
S.E. Clarke, C.R. Lazarus, P. Wraight, C. Sampson, M.N. Maisey, Pentavalent [99mTc] DMSA, [131I] MIBG, and [99mTc]MDP–an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J. Nucl. Med. 29, 33–8 (1988)
pubmed: 2826723
I. Ilias, C. Divgi, K. Pacak, Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin. Nucl. Med. 41, 364–8 (2011)
pubmed: 21803186
pmcid: 3415306
U. Verga, F. Muratori, G. Di Sacco, F. Banfi, A. Libroia, The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma. Henry Ford. Hosp. Med. J. 37, 175–7 (1989)
pubmed: 2576958
A.L. Giraudet, D. Vanel, S. Leboulleux, A. Aupérin, C. Dromain, L. Chami et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185–90 (2007)
pubmed: 17726071
S.C. Ong, H. Schöder, S.G. Patel, I.M. Tabangay-Lim, I. Doddamane, M. Gönen et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J. Nucl. Med. 48, 501–7 (2007)
pubmed: 17401085
G. Treglia, M.F. Villani, A. Giordano, V. Rufini, Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42, 535–45 (2012)
pubmed: 22527889
A. Archier, C. Heimburger, C. Guerin, I. Morange, F.F. Palazzo, J.F. Henry et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 43, 1027–33 (2016)
pubmed: 26497699
M. Beheshti, S. Pocher, R. Vali, P. Waldenberger, G. Broinger, M. Nader et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur. Radio. 19, 1425–34 (2009)
B. Beuthien-Baumann, A. Strumpf, J. Zessin, J. Bredow, J. Kotzerke, Diagnostic impact of PET with 18 F-FDG, 18 F-DOPA and 3-O-methyl-6- [18 F] fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34, 1604–9 (2007)
pubmed: 17435996
G. Glatting, A.K. Buck, C. Solbach, B. Neumaier, S.N. Reske, F.M. Mottaghy, Clinical value of 18- fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20, 527–33 (2010)
pubmed: 20450432
S. Hoegerle, C. Altehoefer, N. Ghanem, I. Brink, E. Moser, E. Nitzsche, 18 F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28, 64–71 (2001)
pubmed: 11202454
S. Kauhanen, C. Schalin-Jantti, M. Seppanen, S. Kajander, S. Virtanen, J. Schildt et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J. Nucl. Med. 52, 1855–63 (2011)
pubmed: 22052128
K.P. Koopmans, L.W.B. de Groot, J.T. Plukker, E.G. de Vries, I.P. Kema, W.J. Sluiter et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 49, 524–31 (2008)
pubmed: 18375923
M. Luster, W. Karges, K. Zeich, S. Pauls, F.A. Verburg, H. Dralle et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20, 527–33 (2010)
pubmed: 20450432
M. Marzola, M. Pelizzo, M. Ferdeghini, A. Toniato, A. Massaro, V. Ambrosini et al. Dual PET/CT with 18F-DOPA and 18F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur. J. Surg. Oncol. (EJSO) 36, 414–21 (2010)
A.R. Romero-Lluch, J.I. Cuenca-Cuenca, R. Guerrero-Vázquez, A.J. Martínez-Ortega, I. Borrego-Dorado, E. Navarro-González, Diagnostic utility of PET/CT with 18 F-DOPA and 18 F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging 44, 2004–13. (2017)
pubmed: 28646462
M. Soussan, V. Nataf, K. Kerrou, D. Grahek, O. Pascal, J.N. Talbot et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl. Med. Commun. 33, 775–9 (2012)
pubmed: 22546877
T. Traub-Weidinger, D. Putzer, E. von Guggenberg, G. Dobrozemsky, B. Nilica, D. Kendler et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur. J. Nucl. Med. Mol. Imaging 42, 1995–2001 (2015)
pubmed: 26173620
G. Treglia, P. Castaldi, M.F. Villani, G. Perotti, C. de Waure, A. Filice et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569–80 (2012)
pubmed: 22223169
G. Treglia, A. Stefanelli, P. Castaldi, V. Rufini, A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. Nucl. Med. Commun. 34, 185–6 (2013)
pubmed: 23111381
H.H. Verbeek, J.T. Plukker, K.P. Koopmans, J.W. de Groot, R.M. Hofstra, A.C. Muller Kobold et al. Clinical relevance of 18F- FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J. Nucl. Med. 53, 1863–71 (2012)
pubmed: 23081996
D.J. Kwekkeboom, J.C. Reubi, S.W. Lamberts, H.A. Bruining, A.H. Mulder, H.Y. Oei, E.P. Krenning, In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 76, 1413–7 (1993)
pubmed: 8501144
D. Puhr-Westerheide, C.C. Cyran, J. Sargsyan-Bergmann, A. Todica, F.J. Gildehaus, W.G. Kunz et al. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18 F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging 19, 73 (2019)
pubmed: 31727170
pmcid: 6857128
L.A. Castroneves, G. Coura Filho, R.M.C. de Freitas, R. Salles, R.A. Moyses, R.V.M. Lopez et al. Comparison of 68Ga PET/CT to other imaging studies in medullary thyroid cancer: superiority in detecting bone metastases. J. Clin. Endocrinol. Metab. 103, 3250–9 (2018)
pubmed: 29846642
B.G. Conry, N.D. Papathanasiou, V. Prakash et al. Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 37, 49–57 (2010)
pubmed: 19662413
E.C.S. de Camargo Etchebehere, S.A. de Oliveira, B. Gumz, A. Vicente, P.G. Hoff, G. Corradi et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J. Nucl. Med. 55, 1598–604 (2014)
D. Putzer, A. Kroiss, D. Waitz, M. Gabriel, T. Traub-Weidinger, C. Uprimny et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur. J. Nucl. Med. Mol. Imaging 40, 364–72 (2013)
pubmed: 23151915
P. Souteiro, P. Gouveia, G. Ferreira, S. Belo, C. Costa, D. Carvalho et al. 68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers. Endocrine 64, 322–9 (2019)
pubmed: 30684230
L.Y.I. Yamaga, M.L. Cunha, G.C. Campos Neto, M.R.T. Garcia, J.H. Yang, C.P. Camacho, et al. 68) Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111) In-octreotide SPECT/CT and conventional imaging. Eur. J. Nucl. Med. Mol. Imaging 44, 1695–701 (2017).
pubmed: 28429044
S.W. Lee, S.R. Shim, S.Y. Jeong, S.J. Kim, Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis. Clin. Nucl. Med. 45, 341–8 (2020)
pubmed: 32049723
C. Bodet-Milin, A. Faivre-Chauvet, T. Carlier, C. Ansquer, A. Rauscher, E. Frampas et al. Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study. J. Nucl. Med. 62, 1221–7 (2021)
pubmed: 33547213
L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Kang, J. Lorch et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N. Engl. J. Med. 383, 825–35 (2020)
pubmed: 32846061
D. Salvatore, M. Santoro, M. Schlumberger, The importance of the RET gene in thyroid cancer and therapeutic implications. Nat. Rev. Endocrinol. 17, 296–306 (2021)
pubmed: 33603219
A. Kaloudi, B.A. Nock, E.P. Krenning, T. Maina, M. De Jong, M. Radiolabeled, gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting. Q J. Nucl. Med. Mol. Imaging 59, 287–302 (2015)
pubmed: 26158215
C. Uprimny, E. von Guggenberg, A. Svirydenka, R. Mikołajczak, A. Hubalewska-Dydejczyk, I.J. Virgolini, Comparison of PET/CT imaging with [(18)F] FDOPA and cholecystokinin-2 receptor targeting [(68) Ga] Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 48, 935–6 (2021)
pubmed: 32748048